---
title: "Canaccord Genuity Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295789301.md"
description: "Canaccord Genuity analyst Edward Nash reiterated a Hold rating on Pliant Therapeutics (PLRX) with a price target of $3.00. The company currently holds an analyst consensus of Hold, with a broader price target consensus of $2.50."
datetime: "2026-08-13T11:18:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295789301.md)
  - [en](https://longbridge.com/en/news/295789301.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295789301.md)
generator: "portal-rs"
---

# Canaccord Genuity Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)

Canaccord Genuity analyst Edward Nash reiterated a Hold rating on Pliant Therapeutics today and set a price target of $3.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Nash covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Corcept Therapeutics, and Kymera Therapeutics. According to TipRanks, Nash has an average return of 31.4% and a 55.78% success rate on recommended stocks. 

Pliant Therapeutics has an analyst consensus of Hold, with a price target consensus of $2.50.

### Related Stocks

- [PLRX.US](https://longbridge.com/en/quote/PLRX.US.md)
- [TVTX.US](https://longbridge.com/en/quote/TVTX.US.md)
- [CORT.US](https://longbridge.com/en/quote/CORT.US.md)
- [KYMR.US](https://longbridge.com/en/quote/KYMR.US.md)

## Related News & Research

- [Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting | PLRX Stock News](https://longbridge.com/en/news/287275540.md)
- [BrainStorm Cell Therapeutics GAAP EPS of -$0.35](https://longbridge.com/en/news/296069988.md)
- [Piper Sandler Reaffirms Their Buy Rating on Akebia Therapeutics (AKBA)](https://longbridge.com/en/news/296105482.md)
- [Mitsubishi UFJ Asset Management Co. Ltd. Purchases Shares of 32,564 Viking Therapeutics, Inc. $VKTX](https://longbridge.com/en/news/296678166.md)
- [BlackRock Inc. Makes New $1.08 Billion Investment in Corcept Therapeutics Incorporated $CORT](https://longbridge.com/en/news/296675400.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**